Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide biomarker study for prevention of actinic keratosis and cutaneous squamous cell carcinoma
2018-000743-66Phase 4Completed
- Sponsor
- Fondazione Luigi Maria Monti IDI-IRCCS
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nicotinamide in actinic keratosis (AK) and cutaneous squamous cell carcinoma (cSCC), sponsored by Fondazione Luigi Maria Monti IDI-IRCCS. Started Jan 2025; status: completed.
02
Drugs
nicotinamide
03
Conditions
actinic keratosis (AK)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2018-000743-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000743-66.